12:00 AM
 | 
Sep 20, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

SG2000: Phase II started

Spirogen began an open-label, U.S. Phase II trial to evaluate 30 µg/m 2/day SG2000 for the first 3 days of a 21-day cycle in about 50 patients. Spirogen has rights to SG2000...

Read the full 138 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >